GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rani Therapeutics Holdings Inc (NAS:RANI) » Definitions » ROC (Joel Greenblatt) %

RANI (Rani Therapeutics Holdings) ROC (Joel Greenblatt) % : -407.17% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Rani Therapeutics Holdings ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Rani Therapeutics Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -407.17%.

The historical rank and industry rank for Rani Therapeutics Holdings's ROC (Joel Greenblatt) % or its related term are showing as below:

RANI' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1157.92   Med: -901.88   Max: -370.82
Current: -514.83

During the past 5 years, Rani Therapeutics Holdings's highest ROC (Joel Greenblatt) % was -370.82%. The lowest was -1157.92%. And the median was -901.88%.

RANI's ROC (Joel Greenblatt) % is ranked worse than
57.73% of 1410 companies
in the Biotechnology industry
Industry Median: -307.695 vs RANI: -514.83

Rani Therapeutics Holdings's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Rani Therapeutics Holdings ROC (Joel Greenblatt) % Historical Data

The historical data trend for Rani Therapeutics Holdings's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rani Therapeutics Holdings ROC (Joel Greenblatt) % Chart

Rani Therapeutics Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
-596.83 -370.82 -1,157.92 -1,061.94 -901.88

Rani Therapeutics Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -948.83 -727.16 -576.93 -414.54 -407.17

Competitive Comparison of Rani Therapeutics Holdings's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Rani Therapeutics Holdings's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rani Therapeutics Holdings's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rani Therapeutics Holdings's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Rani Therapeutics Holdings's ROC (Joel Greenblatt) % falls into.



Rani Therapeutics Holdings ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.133) - (2.394 + 0 + 0.534)
=-1.795

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.967) - (3.25 + 0.6 + 0.183)
=-2.066

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Rani Therapeutics Holdings for the quarter that ended in Sep. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-45.54/( ( (11.446 + max(-1.795, 0)) + (10.923 + max(-2.066, 0)) )/ 2 )
=-45.54/( ( 11.446 + 10.923 )/ 2 )
=-45.54/11.1845
=-407.17 %

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Rani Therapeutics Holdings  (NAS:RANI) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Rani Therapeutics Holdings ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Rani Therapeutics Holdings's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Rani Therapeutics Holdings Business Description

Traded in Other Exchanges
N/A
Address
2051 Ringwood Avenue, San Jose, CA, USA, 95131
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads up to 200 microlitre in liquid form with high bioavailability.
Executives
South Cone Investments Limited Partnership 10 percent owner AVENIDA PRESIDENTE RIESCO 5711 OFICINA 1, LAS CONDES, SANTIAGO F3 7550000
Talat Imran director, officer: CEO C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
Quiroga Cortes Isidoro Alfonso 10 percent owner 9020 N CAPITAL OF TEXAS HWY, SUITE I-260, AUSTIN TX 78759
Jean Luc Butel director ONE BAXTER PARKWAY, DEERFIELD IL 60015
Maulik Nanavaty director BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Kate Mckinley officer: CHIEF BUSINESS OFFICER C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131
Svai S Sanford officer: CFO C/O RANI THERAPEUTICS LLC, 2051 RINGWOOD AVE., SAN JOSE CA 95131
Eric Groen officer: General Counsel C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131
Mir Hashim officer: Chief Scientific Officer C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
South Lake One Llc 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Aequanimitas Limited Partnership 10 percent owner LEONEL AGUIRRE 1830, UNIT 101, MONTEVIDEO X3 11500
Mir A Imran director
Andrew Farquharson director C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVENUE, SAN JOSE CA 95131
Laureen Debuono director
Lisa Ann Rometty director C/O RANI THERAPEUTICS HOLDINGS, INC., 2051 RINGWOOD AVE., SAN JOSE CA 95131